Search for a command to run...
We aim to examine the growing influence of testimonial-based and marketing-driven practices in orthopaedics, particularly in joint arthroplasty, and to highlight how these trends threaten scientific integrity, patient safety and the responsible adoption of novel techniques and technologies. This editorial synthesizes current evidence, regulatory conditions and economic pressures shaping orthopaedic practice. By drawing on published research, examples of marketed surgical approaches and cross-regional comparisons of health-care environments, it critically evaluates how innovations are introduced, promoted and adopted. The discussion emphasizes the contrast between evidence-based processes and commercially driven strategies, including trademarked surgical approaches and subscription-based certification models. A shift from evidence-based to endorsement-driven decision-making is increasingly evident, especially in the United States, where high health-care expenditures and marketing permissiveness enable rapid proliferation of branded surgical approaches. In hip and knee arthroplasty, well-established techniques are frequently rebranded without accompanying scientific validation, while aggressive marketing and certification schemes create misleading perceptions of novelty and superiority. Regulatory constraints in Europe, although imperfect, slow the spread of unproven innovations and require more rigorous evaluation. The combined effects of market pressure, inconsistent oversight and uneven global innovation pathways contribute to a widening gap between marketed claims and actual clinical evidence. Testimonial-driven medicine and commercially motivated rebranding pose substantial risks to patient safety and undermine scientific progress in orthopaedics. Robust regulatory frameworks, adherence to peer-reviewed evidence and active collaboration across institutions and regions are essential to counterbalance market forces. Innovations-whether drugs, devices or surgical techniques-must undergo rigorous preclinical and clinical evaluation before broad implementation. The profession must remain vigilant against practices that bypass scientific scrutiny, ensuring that patient care is guided by validated evidence rather than marketing narratives.